98%
921
2 minutes
20
In the present study, the various concentrations of AuNP (1.25, 2.5, 5, 10 ppm) were prepared to investigate the biocompatibility, biological performances and cell uptake efficiency via Wharton's jelly mesenchymal stem cells and rat model. The pure AuNP, AuNP combined with Col (AuNP-Col) and FITC conjugated AuNP-Col (AuNP-Col-FITC) were characterized by Ultraviolet-visible spectroscopy (UV-Vis), Fourier-transform infrared spectroscopy (FTIR) and Dynamic Light Scattering (DLS) assays. For in vitro examinations, we explored whether the Wharton's jelly MSCs had better viability, higher CXCR4 expression, greater migration distance and lower apoptotic-related proteins expression with AuNP 1.25 and 2.5 ppm treatments. Furthermore, we considered whether the treatments of 1.25 and 2.5 ppm AuNP could induce the CXCR4 knocked down Wharton's jelly MSCs to express CXCR4 and reduce the expression level of apoptotic proteins. We also treated the Wharton's jelly MSCs with AuNP-Col to investigate the intracellular uptake mechanisms. The evidence demonstrated the cells uptake AuNP-Col through clathrin-mediated endocytosis and the vacuolar-type H-ATPase pathway with good stability inside the cells to avoid lysosomal degradation as well as better uptake efficiency. Additionally, the results from in vivo examinations elucidated the 2.5 ppm of AuNP attenuated foreign body responses and had better retention efficacy with tissue integrity in animal model. In conclusion, the evidence demonstrates that AuNP shows promise as a biosafe nanodrug delivery system for development of regenerative medicine coupled with Wharton's jelly MSCs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222259 | PMC |
http://dx.doi.org/10.3390/pharmaceutics15051385 | DOI Listing |
Int J Womens Health
August 2025
Key Laboratory of Evidence Science (China University of Political Science and Law), Ministry of Education, Beijing, 100088, People's Republic of China.
Background: Umbilical cord hemorrhage (UCH) is a rare but catastrophic obstetric emergency associated with nearly 50% fetal mortality, and its precise pathogenic mechanisms remain elusive in clinical practice. The pathophysiological cascade involves hemorrhagic expansion from ruptured umbilical vessels predominantly the umbilical vein which generates compressive forces on adjacent umbilical arteries within the constrained Wharton's jelly. This acute vascular compromise precipitates the sudden cessation of fetoplacental circulation, culminating in irreversible hypoxic-ischemic injury.
View Article and Find Full Text PDFStem Cell Res Ther
September 2025
Department for Small Animals and Horses, Centre for Equine Health and Research, Equine Surgery Unit, Veterinary Tissue Engineering and Regenerative Medicine Laboratory, University of Veterinary Medicine Vienna, Vienna, Austria.
Background: Osteoarthritis (OA) remains an intractable condition due to the limited regenerative capacity of adult cartilage. Extracellular vesicles (EVs) have emerged as promising therapeutics, yet the optimal donor cell source is still undetermined, as both donor cell type and age significantly influence EV therapeutic efficacy. This study evaluates the therapeutic potential of EVs derived from ovine fetal articular chondrocytes (fCCs) and ovine fetal umbilical cord blood mesenchymal stromal cells (fMSCs) compared to EVs from two immortalized human perinatal cell lines, Wharton's jelly (WJ-MSCs) and amnion MSCs (P-MSCs), on inflamed ovine adult chondrocytes and synoviocytes in vitro.
View Article and Find Full Text PDFPharmaceuticals (Basel)
July 2025
Institute of Health Technologies and Preventive Medicine-Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
Cancer treatment has undergone a paradigm shift following the introduction of novel cancer treatment approaches that involve the host's immune system in fighting established tumors. This new concept aids the immune system in identifying, attacking, and killing the tumor cells. However, although some encouraging results were observed clinically, this approach has its own limitations.
View Article and Find Full Text PDFJ Mol Histol
August 2025
Department of Medical Physiology, Faculty of Medicine, Cairo University, Giza, Egypt.
Neurodegener Dis Manag
August 2025
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran.
Introduction: There are a few therapeutic approaches for Amyotrophic Lateral Sclerosis (ALS) which can only slow down or stop the disease progression for a limited period of time. Since it has been proven that Mesenchymal Stromal Cells (MSCs) produce neurotrophic factors and have some neuroprotective effects, stem cell therapy has been proposed as an alternative or add-on treatment for ALS patients.
Method & Material: In this open-label clinical trial, two-repeated dose of 60 million GMP compliant Wharton's Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) were transplanted intrathecally (#6 patients) or intravenously (#6 patients) twice with a 3-month interval.